Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635988 | 0.88 | EGFR (0.62) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL3977060 | 0.86 | EGFR (0.57) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL8200916 | 0.86 | EGFR (0.57) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL3106181 | 0.86 | EGFR (0.57) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4731344 | 0.84 | EGFR (0.56) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL1387173 | 0.84 | EGFR (0.61) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL3976229 | 0.84 | EGFR (0.59) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL11286630 | 0.83 | RAB9A (0.56) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL30117812 | 0.83 | EGFR (0.58) | EGFRRAB9ANPC1TSHRL3MBTL1 | |
| SCHEMBL3980790 | 0.82 | EGFR (0.54) | EGFRRAB9ANPC1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031561-B | 4-phenoxy-containing quinazoline compound and application thereof | 江西科技师范大学 | 2022-12-02 | — | — | CN | claimed |
| CN-114031561-A | 4-phenoxy-containing quinazoline compound and application thereof | 江西科技师范大学 | 2022-02-11 | — | — | CN | claimed |
| WO-2023085225-A1 | METHOD FOR MANUFACTURING RECYCLED RESIN COMPOSITION | 住友化学株式会社 | 2023-05-19 | — | — | WO | disclosed |
| CN-114031561-B | 4-phenoxy-containing quinazoline compound and application thereof | 江西科技师范大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-114031561-A | 4-phenoxy-containing quinazoline compound and application thereof | 江西科技师范大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-104211649-A | Preparation method of quinazoline-4(3H)-ketone and application | UNIV FUDAN | 2014-12-17 | — | — | CN | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009058937-A2 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058937-A2 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
| US-6630489-B1 | Quinoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| EP-1157008-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000050405-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | EGFR 265/4885RAB9A 1540/4885NPC1 284/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | EGFR 265/4885RAB9A 1540/4885NPC1 284/4885 |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | EGFR 456/4885RAB9A 3568/4885NPC1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.